Included patients' main demographics, clinical characteristics, and DMT
| Demographics | |
|---|---|
| No. of evaluable patients | 232 |
| Relapsing-emitting MS | 177 (76.3%) |
| Secondary-progressive MS | 20 (8.6%) |
| Primary-progressive MS | 10 (4.3%) |
| CIS (%) | 21 (9.1%) |
| RIS (%) | 4 (1.7%) |
| Age (mean) (yr) | 46 (SD, 12.65) |
| Sex (men/women) | 81:151 |
| EDSSa (median) (interquartile range) | 2.5/2 |
| Disease durationa (median) (interquartile range) | 11/11 |
| DMT efficacyb | |
| Moderatec | 126 (60.9%) |
| Highd | 9 (4.3%) |
| Very highe | 36 (17.4%) |
| No DMT | 36 (17.4%) |
Note:—CIS indicates clinically isolated syndrome; RIS, radiologically isolated syndrome; EDSS, Expanded Disability Status Scale; DMT, disease-modifying treatment.
↵a Patients with relapsing-remitting, secondary-progressive, or primary-progressive MS only.
↵b According to Dobson et al.28
↵c Includes dimethyl fumarate, glatiramer acetate, interferon-β 1-α, interferon-β-1b, and teriflunomide.
↵d Includes fingolimod, siponimod, and ozanimod.
↵e Includes alemtuzumab, cladribine, mitoxantrone, natalizumab, and ocrelizumab.